Authors:
Fitzgerald, AJ
Jordinson, M
Rhodes, JM
Singh, R
Calam, J
Goodlad, RA
Citation: Aj. Fitzgerald et al., Comparison of the effects of concanavalin-A and epidermal growth factor onepithelial cell proliferation in the rat intestine, ALIM PHARM, 15(7), 2001, pp. 1077-1084
Citation: K. Neal et R. Logan, Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors, ALIM PHARM, 15(7), 2001, pp. 1085-1085
Citation: L. Laine, Reply - potential gastrointestinal effects of longterm acid suppression with proton pump inhibitors, ALIM PHARM, 15(7), 2001, pp. 1085-1086
Citation: R. Jones et P. Bytzer, Review Article: Acid suppression in the management of gastro-oesophageal reflux disease - an appraisal of treatment options in primary care, ALIM PHARM, 15(6), 2001, pp. 765-772
Authors:
Horai, Y
Kimura, M
Furuie, H
Matsuguma, K
Irie, S
Koga, Y
Nagahama, T
Murakami, M
Matsui, T
Yao, T
Urae, A
Ishizaki, T
Citation: Y. Horai et al., Pharmacodynamic effects and kinetic disposition of rabeprazole in relationto CYP2C19 genotypes, ALIM PHARM, 15(6), 2001, pp. 793-803
Authors:
Azuma, T
Ito, Y
Suto, H
Ohtani, M
Dojo, M
Muramatsu, A
Kuriyama, M
Kato, T
Citation: T. Azuma et al., The effect of Helicobacter pylori eradication therapy on dyspepsia symptoms in industrial workers in Japan, ALIM PHARM, 15(6), 2001, pp. 805-811
Authors:
Koike, T
Ohara, S
Sekine, H
Iijima, K
Kato, K
Toyota, T
Shimosegawa, T
Citation: T. Koike et al., Increased gastric acid secretion after Helicobacter pylori eradication maybe a factor for developing reflux oesophagitis, ALIM PHARM, 15(6), 2001, pp. 813-820
Authors:
Capurso, G
Annibale, B
Osborn, J
D'Ambra, G
Martino, G
Lahner, E
Delle Fave, G
Citation: G. Capurso et al., Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection, ALIM PHARM, 15(6), 2001, pp. 821-829
Authors:
Fischbach, LA
Correa, P
Ramirez, H
Realpe, JL
Collazos, T
Ruiz, B
Bravo, LE
Bravo, JC
Casabon, AL
Schmidt, BA
Citation: La. Fischbach et al., Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer, ALIM PHARM, 15(6), 2001, pp. 831-841
Citation: Bcy. Wong et al., Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study, ALIM PHARM, 15(6), 2001, pp. 843-849
Authors:
Meier, R
Wettstein, A
Drewe, J
Geiser, HR
Citation: R. Meier et al., Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication, ALIM PHARM, 15(6), 2001, pp. 851-855
Authors:
Matrella, E
Valatas, V
Notas, G
Roumpaki, H
Xidakis, C
Hadzidakis, A
Mouzas, I
Kouroumalis, E
Citation: E. Matrella et al., Bolus somatostatin but not octreotide reduces hepatic sinusoidal pressure by a NO-independent mechanism in chronic liver disease, ALIM PHARM, 15(6), 2001, pp. 857-864
Authors:
Naito, Y
Takagi, T
Matsuyama, K
Yoshida, N
Yoshikawa, T
Citation: Y. Naito et al., Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats, ALIM PHARM, 15(6), 2001, pp. 865-873
Authors:
Xiao, F
Furuta, T
Takashima, M
Shirai, N
Hanai, H
Citation: F. Xiao et al., Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice, ALIM PHARM, 15(6), 2001, pp. 875-886
Citation: At. Helmy et Pc. Hayes, Review article: current endoscopic therapeutic options in the management of variceal bleeding, ALIM PHARM, 15(5), 2001, pp. 575-594
Authors:
Janssen, MJR
Van Oijen, AHAM
Verbeek, ALM
Jansen, JBMJ
De Boer, WA
Citation: Mjr. Janssen et al., A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plusclarithromycin and either amoxicillin or a nitroimidazole, ALIM PHARM, 15(5), 2001, pp. 613-624
Authors:
Hawkes, ND
Richardson, C
Evans, BK
Rhodes, J
Lewis, SJ
Thomas, GAO
Citation: Nd. Hawkes et al., Effect of an enteric-release formulation of naloxone on intestinal transitin volunteers taking codeine, ALIM PHARM, 15(5), 2001, pp. 625-630
Citation: Mr. Arguedas et al., Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis, ALIM PHARM, 15(5), 2001, pp. 631-638